103-LB: Comparison of Two Hyperglycemia Correction Scales in Hospitalized Patients with Diabetes Mellitus Type 2—CAPADOCIA 2 Trial
2022; American Diabetes Association; Volume: 71; Issue: Supplement_1 Linguagem: Inglês
10.2337/db22-103-lb
ISSN1939-327X
AutoresCarlos Augusto Yepes, Javier Mauricio Mora Méndez, Evelyn Ospina, JORGE ALEJANDRO R. RODRÍGUEZ, LAURA A. LEÓN, JAVIER GOMEZ, NATHALIE BURITICÁ,
Tópico(s)Public Health and Environmental Issues
ResumoIntroduction: We evaluated the efficacy and safety of the recommended scheme by international guideline in 2012 (2012’s scheme) in comparison with a less aggressive scheme (2019’s scheme) proposed by Umpierrez et al. Methods: A non-blinded randomized clinical study was conducted in which two short-time insulin schemes for hyperglycemic control (2012’s vs. 2019’s) were compared in hospitalized patients of Hospital Universitario Clínica San Rafael (HUCSR) in Bogotá Colombia in a period between october 2019 and february 2022. Results: Totally, 91 patients joined the trial. There were no statically significant difference between the demographic characteristics and outcomes. Conclusions: The two schemes are equally safe and efficient in our population and can be used interchangeably. Disclosure C. A. Yepes: Speaker’s Bureau; Medtronic, Novo Nordisk, Sanofi. J. M. Mora: None. E. Moscoso: None. J. R. Rodríguez: None. L. A. León: None. J. Gomez: None. N. Buriticá: None.
Referência(s)